Articles > Insulins & Non-insulins

  1. Nasal Glucagon Proves Effective in Real-World Conditions

    Trial participants also reported that the experimental glucagon was easy to use in the two late-phase trials. -Craig Idlebrook/GluCraig Data from two new studies provide evidence that nasal glucagon could be an effective treatment for hypoglycemia in a real-world setting. The two Phase III studies, funded by Eli Lilly and Locemia Solutions, aimed to gauge whether […]

    Read More
  1. FDA Asked to Approve Sotagliflozin for Type 1 Diabetes

      Sanofi has asked the FDA to approve the dual SGLT1 and SGLT2 inhibitor as a possible add-on to insulin therapy. The FDA has been asked to approve just the second adjunct (or add-on) therapy for those with type 1 diabetes. Sanofi has submitted a New Drug Application for sotagliflozin, an oral drug therapy that […]

    Read More
  2. Half-Unit Insulin Pen Survey

    Glu has a new opportunity to get involved in research! In this study, we aim to understand characteristics of people with type 1 diabetes who have used and who have never used half-unit insulin pens, as well as preferences in devices. Whether you currently use a half-unit insulin pen, used one in the past, or […]

    Read More
  3. Project Pizza: A Slice of T1D Research with GluAlex

    Has there ever been a food more beloved and yet more challenging for people with type 1 diabetes? Something about that high carb/high fat mix makes pizza both incredibly delicious and incredibly difficult to control blood sugar! Here at Glu, GluAlex attempted to find the right pizza bolus. Here’s what he learned: Project Pizza Night […]

    Read More
  1. Join Glu in Central Massachusetts for Family Diabetes Day!

    Diabetes Day Mailer cropped

    Central Mass folks-come join us at the Family Diabetes Day! Glu is co-hosting this program with the American Diabetes Association to bring you a day of fun for all ages. We’ll have age-appropriate break outs for kids, teens, parents, and adults with type 1 as well as panel discussions and research updates including the Bionic […]

    Read More
  2. SGLT-2 Inhibitors Associated with DKA in Type 1 Patients, Warnings Now Required

    Close-up looking over a woman's shoulder to her holding a bottle of prescription medication

    The FDA recently mandated that users of SGLT-2 inhibitor drugs be warned of the risks of diabetic ketoacidosis (DKA) after receiving more than 70 reports of DKA. The agency previously issued a safety statement regarding these drugs’ potential dangerous side effects. SGLT-2 inhibitors, such as empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana), are a promising […]

    Read More
  3. Steroid Medications Can Increase Insulin Requirements

    Vials of Pills

    Here’s what you need to know.  Type 1 diabetes (T1D) care, and particularly glycemic control, does not exist in a vacuum. Even if someone with T1D were to eat the exact same diet every day, his or her insulin requirements could still change. Exercise, stress, and environmental factors can have huge impacts on blood sugar […]

    Read More
  4. New Film Explains Monogenic Diabetes

    cover photo plain600

    An intriguing film was shown at this year’s ADA Scientific Sessions in Boston. Journey of a Miracle: Freedom from Insulin tells the story of several families who had children who were diagnosed with type 1 diabetes, but actually had monogenic diabetes. Dr. Louis Philipson of the University of Chicago introduced the film to the standing-room-only […]

    Read More
  5. FDA Issues Safety Statement that SGLT-2 Inhibitors May Cause Diabetic Ketoacidosis

    Anne Peters MD

    [Editor’s note: several months ago, we ran an article after Dr. Anne Peters of the University of Southern California reported some patients who took SGLT-2 inhibitors like Invokana off-label experienced diabetic ketoacidosis (DKA) while ill and even having evidently normal blood glucose levels. Our friends at diaTribe have posted an update after the FDA recently […]

    Read More
  6. Glu Event Recap & Podcast: Examining Insulins of Today and Tomorrow

    combo bolus

    This event was recorded and is available to stream or download here. Cover the carbs, correct highs, treat lows and don’t correct in under three hours from the last bolus. That, in a nutshell, is what my husband and I have been doing for our son Miles for the past year and a half. Perhaps […]

    Read More